If you have been searching how to get retatrutide in Australia, the honest answer in late September 2026 is narrower than it was a year ago — and the reason is buried in clinical trial registry listings rather than in any announcement. Australia genuinely was part of Eli Lilly's Phase 3 retatrutide programme, with sites listed in multiple states. But the trials that carried those Australian sites have already read out. The research door that a handful of Australians walked through is, for practical purposes, closed, and there is no approved product waiting on the other side.

This post sticks to what the registries and the published trial design paper actually say.

How to Get Retatrutide in Australia: What the Registry Listings Show

Retatrutide is not registered by the TGA. It is an investigational triple agonist — GLP-1, GIP and glucagon receptors at once — and Lilly has indicated filing from 2027. That leaves exactly one legitimate pathway that has ever existed in this country: enrolment in a sponsor-run clinical trial. (Background on the molecule itself is in what is retatrutide.)

Two registry records make the Australian footprint concrete:

  • NCT05929066, the large Phase 3 study in adults with obesity or overweight, lists Australian sites including Botany and Merewether in New South Wales, Meadowbrook in Queensland, two Adelaide sites in South Australia, Camberwell and Geelong in Victoria, and Nedlands in Western Australia.
  • NCT05931367 (TRIUMPH-4), the stand-alone knee osteoarthritis trial, lists Australian sites in Bruce (ACT) and Blacktown (NSW).

That is a real national spread — eight states-and-territories worth of metropolitan and regional research centres. It is also a small number of slots relative to a country where roughly 66.8% of adults are living with overweight or obesity.

Why those doors are shut

Both of those trials have already produced their headline results. TRIUMPH-4's readout is public: participants on the two highest investigational doses lost up to 28.7% of body weight at 68 weeks, alongside knee osteoarthritis pain improvement. A trial that has reported its primary endpoint is not recruiting new participants.

The practical takeaway for Australian readers: searching "retatrutide trials near me" in 2026 is far more likely to return a site that once enrolled than one that is enrolling now. Registry status does change, and new protocols get posted, so the only reliable check is ClinicalTrials.gov and the Australian New Zealand Clinical Trials Registry (ANZCTR) — not a clinic's marketing page. Our running summary of the programme is at clinical trials.

The Trial Design Paper Explains Why Slots Were So Tight

In January 2026, Diabetes, Obesity and Metabolism published the rationale-and-design paper for the TRIUMPH registrational programme (Giblin et al.). It is worth reading because it shows the enrolment maths.

TRIUMPH is four Phase 3 randomised, double-blind, placebo-controlled studies in more than 5,800 participants across dozens of countries. Two of them (TRIUMPH-1 and TRIUMPH-2) are weight-management "basket" trials with obstructive sleep apnoea and/or knee osteoarthritis protocols nested inside them. TRIUMPH-3 is a weight-management trial in people with cardiovascular disease. TRIUMPH-4 is the stand-alone knee osteoarthritis study.

Endpoints differ by basket: percent change in body weight for weight management, change in the Apnoea-Hypopnoea Index for sleep apnoea, and change in the WOMAC pain subscale for knee osteoarthritis.

Spread 5,800-odd participants across four protocols, three condition baskets and a global site network, and the Australian share was always going to be modest. This is not a gatekeeping conspiracy; it is arithmetic.

The Australian condition overlap is the interesting part

The programme deliberately targets obesity plus two mechanical and respiratory complications. Knee osteoarthritis and sleep apnoea are exactly the conditions that fill Australian orthopaedic and sleep clinic waiting lists. In TRIUMPH-4, Lilly also reported a post-hoc analysis in which roughly 1 in 8 retatrutide-treated participants described themselves as completely free of knee pain at week 68, versus just over 4% on placebo. Post-hoc means the analysis was not the pre-specified primary test — it is a signal to watch, not a proven claim, and it has not yet appeared in a peer-reviewed publication of the trial.

What This Means If You Were Hoping to Access It

  • There is no TGA-registered retatrutide product in Australia. Nothing in the current evidence changes that.
  • The clinical trial route has been the only formal access route, and the Australian-listed studies we can verify have already reported.
  • Tolerability matters as much as efficacy in these programmes; the gastrointestinal and dose-escalation picture is covered in safety.
  • For Australia-specific regulatory context, see australia.

If you want to know the moment an Australian regulatory step or a new local trial listing appears, join the free updates list. We send confirmed developments only.

FAQ

How to get retatrutide in Australia in 2026?

There is currently no approved way — retatrutide is not TGA-registered. The only formal route has been enrolment in an Eli Lilly clinical trial, and the Australian-listed Phase 3 studies we can verify (NCT05929066 and TRIUMPH-4/NCT05931367) have already reported their results and are not open to new participants.

Were there retatrutide clinical trials in Australia?

Yes. Registry listings show Australian sites in New South Wales, Queensland, South Australia, Victoria, Western Australia and the ACT across the obesity study NCT05929066 and the knee osteoarthritis study TRIUMPH-4 (NCT05931367).

Is retatrutide TGA approved yet?

No. Retatrutide remains investigational worldwide, and Eli Lilly has indicated it plans to begin regulatory filings from 2027. No TGA decision timeline has been published.

How do I find a retatrutide trial near me in Australia?

Search ClinicalTrials.gov and the Australian New Zealand Clinical Trials Registry (ANZCTR) directly, and talk to your GP or an endocrinologist about eligibility. Trial statuses change, so a registry record is more current than any clinic's promotional page.

Sources

Disclaimer: This article is general information only and is not medical advice. Retatrutide is an investigational medicine and is not approved by the TGA or any regulator. Speak to your GP or a qualified health professional about your own circumstances. retatrutide.net.au is independent and not affiliated with, endorsed by or sponsored by Eli Lilly and Company.